IRIS
IACOBELLI, Stefano
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 4.716
NA - Nord America 4.668
AS - Asia 1.847
Continente sconosciuto - Info sul continente non disponibili 13
SA - Sud America 6
OC - Oceania 3
AF - Africa 1
Totale 11.254
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.661
UA - Ucraina 1.005
CN - Cina 987
IE - Irlanda 884
GB - Regno Unito 688
SE - Svezia 624
TR - Turchia 598
FR - Francia 577
IT - Italia 398
DE - Germania 268
IN - India 198
FI - Finlandia 187
BE - Belgio 36
VN - Vietnam 24
RU - Federazione Russa 16
PL - Polonia 14
EU - Europa 12
IL - Israele 10
IR - Iran 9
HK - Hong Kong 7
CA - Canada 4
GR - Grecia 4
JP - Giappone 4
BR - Brasile 3
CH - Svizzera 3
ID - Indonesia 3
RO - Romania 3
TW - Taiwan 3
AU - Australia 2
ES - Italia 2
MX - Messico 2
NL - Olanda 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AR - Argentina 1
AT - Austria 1
CZ - Repubblica Ceca 1
EG - Egitto 1
KR - Corea 1
LA - Repubblica Popolare Democratica del Laos 1
LT - Lituania 1
MK - Macedonia 1
NZ - Nuova Zelanda 1
PR - Porto Rico 1
PT - Portogallo 1
PY - Paraguay 1
TH - Thailandia 1
UZ - Uzbekistan 1
VE - Venezuela 1
Totale 11.254
Salva come PNG Salva come JPEG
Città #
Jacksonville 1.104
Chandler 1.095
Dublin 879
Southend 582
Princeton 399
Izmir 337
Nanjing 317
Wilmington 188
Cambridge 183
Beijing 177
Ann Arbor 129
Nanchang 114
Boardman 107
Dearborn 105
Ashburn 99
Altamura 93
Woodbridge 66
Chieti 61
Hebei 54
Shenyang 51
Tianjin 48
Kunming 44
New York 39
Brussels 35
Jiaxing 31
Norwalk 27
Hangzhou 25
Dong Ket 24
Changsha 22
Los Angeles 22
Houston 21
Falls Church 19
Grevenbroich 19
Kocaeli 18
Montesilvano 17
Collecorvino 16
Washington 16
Auburn Hills 15
Lanzhou 15
Leawood 15
Kraków 14
Orange 14
San Mateo 14
Jinan 13
Rome 13
Augusta 12
Guangzhou 10
Ardabil 9
Changchun 9
Düsseldorf 9
Pescara 9
Helsinki 8
Ningbo 8
Taizhou 8
Milan 7
Pune 7
Seattle 7
Tappahannock 7
Chicago 6
Hong Kong 6
Mcallen 6
Andover 5
Finale Ligure 5
Hefei 5
Monmouth Junction 5
Simi Valley 5
Zhengzhou 5
Anzio 4
Mumbai 4
Spoltore 4
Bangalore 3
Città Sant'Angelo 3
Francavilla al Mare 3
Fuzhou 3
Keputih 3
London 3
Munich 3
Napoli 3
Pusiano 3
Redwood City 3
Rio de Janeiro 3
Taipei 3
Baotou 2
Castellamonte 2
Cattolica 2
Cedar Knolls 2
Chengdu 2
Civitanova Marche 2
Dübendorf 2
Greifswald 2
Jinhua 2
Lambeth 2
Leicester 2
Madrid 2
Mexico City 2
Ortona 2
Ragusa 2
San Salvo 2
Shanghai 2
Sibiu 2
Totale 6.938
Salva come PNG Salva come JPEG
Nome #
A phase I study of recombinant interferon-alpha administered as a seven-day continuous venous infusion at circadian-rhythm modulated rate in patients with cancer. 101
90K (Mac-2 BP) and galectins in tumor progression and metastasis. 95
A comparative study of the antiinflammatory, anticoagulant, antiangiogenic, and antiadhesive activities of nine different fucoidans from brown seaweeds 94
The 90K protein increases major histocompatibility complex class I expression and is regulated by hormones, gamma-interferon, and double-strand polynucleotides. 94
A phase II study of dose-dense epirubicin plus cyclophosphamide followed by docetaxel plus capecitabine and pegfilgrastim support as preoperative therapy for patients with stage II, IIIA breast cancer. 93
The 90K tumor associated antigen and clinical progression in human immunodeficiency virus infection 92
EV20-mediated delivery of cytotoxic auristatin MMAF exhibits potent therapeutic efficacy in cutaneous melanoma 91
EV20-Sap, a novel anti-HER-3 antibody-drug conjugate, displays promising antitumor activity in melanoma 91
High expression of 90K (Mac-2 BP) is associated with poor survival in node-negative breast cancer patients not receiving adjuvant systemic therapies 91
Breast cancer "tailored follow-up" in Italian oncology units: A web-based survey 91
An immunohistochemically positive E-cadherin status is not always predictive for a good prognosis in human breast cancer. 90
Purification and characterization of a 90 kDa protein releasedfrom human tumors and tumor cell lines 89
Overexpression of PY1289-HER3 in sporadic pulmonary carcinoid from patients bearing MEN1 gene variants 89
Secreted Gal-3BP is a novel promising target for non-internalizing Antibody–Drug Conjugates 88
Functional and prognostic significance of the genomic amplification of frizzled 6 (FZD6) in breast cancer 88
ERBB3 BINDING ANTIBODY 85
90K (Mac-2 BP) in human milk 84
Patterns of K-ras mutation in colorectal carcinomas from Iran and Italy (a Gruppo Oncologico dell'Italia Meridionale study): influence of microsatellite instability status and country of origin. 84
Elevated serum levels of 90K/MAC-2BP predict unresponsiveness to alfa-interferon therapy in chronic HCV hepatitis patients 82
Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer 82
Inhibition of tumor growth and angiogenesis by SP-2, an anti-lectin, galactoside-binding soluble 3 binding protein (LGALS3BP) antibody. 82
ErbB-3 activation by NRG-1β sustains growth and promotes vemurafenib resistance in BRAF-V600E colon cancer stem cells (CSCs) 82
Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts. 81
Unknown primary tumors 80
Anthropometric, clinical and molecular determinants of treatment outcomes in postmenopausal, hormone receptor positive metastatic breast cancer patients treated with fulvestrant: Results from a real word setting 80
Prognostic relevance of LGALS3BP in human colorectal carcinoma 80
90K protein in HIV infection: evidence of its release from peripheral blood mononuclear cells 79
A phase II study of cisplatin, epirubicin, vindesine chemotherapy and lonidamine in advanced nonsmall cell lung cancer 79
null 79
An Epigenetic Approach to Pancreatic Cancer Treatment: the Prospective Role of Histone Deacetylase Inhibitors 78
A phase I study of 5-day continuous venous infusion of carboplatin at circadian rhythm-modulated rate compared with constant rate 77
Dual targeting of ErbB-2/ErbB-3 results in enhanced antitumor activity in preclinical models of pancreatic cancer. 77
Surgical treatment of adrenal metastases from non small cell lung cancer 76
A phase I study of 5-day continuous venous infusion of carboplatin at circadian rhythm-modulated rate compared with constant rate. 74
Relief of symptoms after gefitinib is associated with improvement of rest/activity rhythm in advanced lung cancer 73
A 90-kDa protein serum marker for the prediction of progression to AIDS in a cohort of HIV-1+ homosexual men. 73
90k is a serum marker of poor-prognosis in non-hodgkins-lymphoma patients. 73
Long-term outcome of neoadjuvant systemic therapy for locally advanced breast cancer in routine clinical practice. 73
Pharmacokinetics of pegylated liposomal doxorubicin administered by intraoperative hyperthermic intraperitoneal chemotherapy to patients with advanced ovarian cancer and peritoneal carcinomatosis 73
A phase I study of 5-day continuous venous infusion of carboplatin (CBDCA) at circadian rhythm-modulated rate 72
Prognostic value of a novel circulating serum 90K antigen in breast cancer 72
Role of 90K protein in asthma and TH2-type cytokine expression. 72
Upstream stimulatory factor regulates constitutive expression and hormonal suppression of the 90K (Mac-2BP) protein. 72
90K (MAC-2 BP) gene expression in breast cancer and evidence for the production of 90K by peripheral-blood mononuclear cells 71
Prognostic value of 90K protein in HIV infection 70
Preoperative dose-dense sequential chemotherapy of epirubicin/cyclophosphamide followed by docetaxel/capecitabine in patients with breast cancer 70
null 70
Novel inhibitors of pvhl-elongin c binding 70
Arterial Thrombosis in ambulatory cancer patients treated with chemotherapy. 70
Adhesion to 90K (Mac-2 BP) as a mechanism for lymphoma drug resistance in vivo. 69
The use of pegylated liposomal doxorubicin with hyperthermic intraperitoneal chemotherapy(HIPEC) in patients undergoing cytoreductive surgery (CS) for peritoneal carcinomatosis ofovarian origin 69
Increased levels of soluble P-selectin in hypercholesterolemic patients 68
Changes of topoisomerase IIalpha expression in breast tumors after neoadjuvant chemotherapy predicts relapse-free survival 68
DNA ploidy and S-phase fraction in pulmonary carcinoids. 68
Inhibition of the Phosphatidylinositol 3-kinase/Akt Pathway by Inositol Pentakisphosphate Results in Antiangiogenic and Antitumor Effects. 68
Lack of expression of galectin-3 is associated with a poor outcome in node-negative patients with laryngeal squamous-cell carcinoma. 67
Analisi dello stato mutazionale di K-RAS: un nuovo strumento per la selezione dei pazienti candidati a terapia con anticorpi anti-EGFR 67
Expression of tumor associated 90K-antigen in human breast cancer: no correlation with prognosis and response to first-line therapy with tamoxifen 66
Axillary Lymph Node Nanometastases are Prognostic Factors for Disease-Free Survival and Metastatic Relapse in Breast Cancer Patients 66
[Hairy cell leukemia: prognosis and treatment] 65
Concentrations of Galectin-3 in the Sera of Normal Controls and Cancer Patients 65
Molecular mechanisms of endocrine resistance and their implication in the therapy of breast cancer 65
Lipoprotein 90K in human immunodeficiency virus-infected patients: a further serologic marker of progression. 65
Generation of a novel Antibody-Drug Conjugate targeting endosialin: potent and durable antitumor response in sarcoma 65
Tyrosine kinase inhibitors 65
Combined therapy in pancreatic cancer 64
Incidental venous thromboembolism in ambulatory cancer patients receiving chemotherapy 64
Bone marrow micrometastases detected by a monoclonal antibody in patients with breast cancer. 64
A multicenter phase II study of Epirubicin with low-dose Herceptin as a first line treatment in HER-2 overexpressing metastatic breast cancer 64
Tumor-associated antigen 90K activates myelomonocytic cell line THP-1 63
A Stochastic Model for the HIV/AIDS Dynamic Evolution 63
A PHASE II STUDY OF NEOADJUVANT CHEMOTHERAPY WITH CISTAPLIN, EPIRUBICIN AND VP – 16 FOR STAGE III UNRESECTABLE NON-SMALL CELL LUNG CANCER 62
The mechanism involved in the regulation of phospholipase Cgamma1 activity in cell migration. 62
90K protein: a new predictor marker of disease progression in human immunodeficiency virus infection. 62
New Targets for Therapy in Pancreatic Cancer 62
Tumor-derived microvesicles: The metastasomes. 62
Phospholipase Cgamma1 is required for metastasis development and progression 61
Unusually high level of a tumor-associated antigen in the serum of human immunodeficiency virus-seropositive individuals. 61
Tumor-associated antigen 90K activates myelomonocytic cell line THP-1. 61
90K (Mac-2 BP) in human milk. 61
Peritoneal Mesothelial Cells as a Significant Source of Ascitic Immunostimulatory Protein 90K 60
Neoadjuvant Chemotherapy for Surgically Staged IIIA N2 Non-Small Cell Lung Cancer (NSCLC) in the Elderly 60
Chronomodulated infusion of cisplatin, 5-fluorouracil and folinic acid: lack of activity in advanced colorectal cancer. 60
Synthetic lactulose amines: novel class of anticancer agents that induce tumor-cell apoptosis and inhibit galectin-mediated homotypic cell aggregation and endothelial cell morphogenesis. 60
Lack of prognostic value of immunohistochemical determination of epidermal growth-factor receptors in human prostate-cancer. 60
Prognostic value of a novel circulating serum 90K antigen in HIV-infected haemophilia patients. 60
Asymptomatic venous thromboembolism in patients with solid tumors treated with chemotherapy: An underestimated phenomenon 60
Pancreatic juice 90K and serum CA 19-9 combined determination can discriminate between pancreatic cancer and chronic pancreatitis. 59
Flavonoids inhibit melanoma lung metastasis by impairing tumor cells endothelium interactions. 59
Dynamic test with recombinant interferon-alpha-2b: effect on 90K and other tumour-associated antigens in cancer patients without evidence of disease. 59
DNA and S-phase fraction analysis by flow cytometry in prostate cancer. Clinicopathologic implications. 59
Elevated Plasma Levels of 90K (Mac-2 BP) Immunostimulatory Glycoprotein in HIV-1-Infected Children 58
Expression of the 90K tumor-associated protein in benign and malignant melanocytic lesions. 58
Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones. 58
Differential effect on TCR: CD3 stimulation of a 90-kD glycoprotein (gp90/Mac-2BP), a member of the scavenger receptor cysteine-rich domain protein family 57
Combinations of biological response modifiers: rationale and clinical responses. 57
A multicentre, double-blind, randomised trial comparing ondansetron versus ondansetron plus dexamethasone in the prophylaxis of cisplatin-induced delayed emesis. 57
HCV genotype and serum 90K levels: host and virus related factors predict response to a-ifn therapy 56
Differential effect on TCR:CD3 stimulation of a 90-kD glycoprotein (gp90/Mac-2BP), a member of the scavenger receptor cysteine-rich domain protein family 56
Novel P53 mutations detected by FAMA in colorectal cancers. 56
Totale 7.143
Salva come PNG Salva come JPEG
Categoria #
all - tutte 36.772
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 36.772
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019420 0 0 0 0 0 0 0 0 0 0 16 404
2019/20202.398 802 189 9 90 149 111 262 235 101 191 246 13
2020/20211.222 192 9 204 10 108 238 36 15 59 200 88 63
2021/2022757 11 12 5 141 90 16 15 54 65 14 98 236
2022/20232.903 217 293 179 375 320 622 166 228 343 26 75 59
2023/20241.104 111 41 101 59 70 369 272 40 14 23 4 0
Totale 11.640